All‐cause mortality · women with operable primary breast cancer
Radiotherapy alone showed no clear difference in all‐cause mortality compared with full axillary surgery (high certainty).
1 finding from 1 review
Local recurrence · women with operable primary breast cancer
Radiotherapy alone leads to lower local recurrence compared with full axillary surgery (high certainty).
1 finding from 1 review
Locoregional recurrence · women with breast cancer and one to three positive lymph nodes
Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) may leads to lower local and regional recurrence (LRR) compared with no PMRT (low certainty).
1 finding from 1 review
Overall survival (OS) · women with breast cancer and one to three positive lymph nodes
Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) probably leads to lower overall survival (OS) compared with no PMRT (moderate certainty).
1 finding from 1 review
Disease-free survival · women with breast cancer and one to three positive lymph nodes
1 finding from 1 review
Time to progression · women with breast cancer and one to three positive lymph nodes
1 finding from 1 review
Short‐term adverse events · women with breast cancer and one to three positive lymph nodes
1 finding from 1 review
Long‐term adverse events · women with breast cancer and one to three positive lymph nodes
1 finding from 1 review
QoL · women with breast cancer and one to three positive lymph nodes
1 finding from 1 review
Local recurrence · breast‐conserving radiotherapy for breast cancer
Boost may leads to lower local control: recurrence at 5 years compared with no boost (low certainty).
1 finding from 1 review
Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer
Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).
1 finding from 1 review
Disease-free survival (new disease, progression or mortality) · breast‐conserving radiotherapy for breast cancer
Boost showed no clear difference in disease‐free survival: disease progression/mortality at 5 years compared with no boost (low certainty).
1 finding from 1 review
Late toxicity, pBRA · breast‐conserving radiotherapy for breast cancer
It is very uncertain whether boost changes late toxicity, pBRA compared with no boost (very low certainty).
1 finding from 1 review
Cosmesis · breast‐conserving radiotherapy for breast cancer
Boost may leads to higher cosmesis, panel scored: fair or poor compared with no boost (low certainty).
2 findings from 1 review
Sensitivity analysis: local control ‐ recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower sensitivity analysis: local control ‐ recurrence at 5 years compared with no boost (high certainty).
1 finding from 1 review
Subgroup analysis: local control ‐ > 40 years old, recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower subgroup analysis: local control ‐ > 40 years old, recurrence at 5… compared with no boost (high certainty).
1 finding from 1 review
Physical fitness · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Fatigue · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Cancer‐specific quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review
Health‐related quality of life · women receiving adjuvant therapy (chemo‐ or radiotherapy or both) for breast cancer
1 finding from 1 review